Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Imaging robust microglial activation after lipopolysaccharide administration in humans with PET.
High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases.
First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks.
Spinal cord quantitative MRI discriminates between disability levels in multiple sclerosis.
Dynamic imaging of individual remyelination profiles in multiple sclerosis.
A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.
Increased PK11195 PET binding in the cortex of patients with MS correlates with disability.
Vitamin D receptor binding, chromatin states and association with multiple sclerosis.
Sex-related factors in multiple sclerosis susceptibility and progression.
Poor sleep in patients with multiple sclerosis.
Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis
Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats.
Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro.
A gradient in cortical pathology in multiple sclerosis by in vivo quantitative 7 T imaging.
Identification of the LDL Receptor-Related Protein-1 Interactome in Central Nervous System myelin suggests a role in the clearance of necrotic cell debris.
Control of experimental autoimmune uveoretinitis by low dose T cell vaccination.
Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study.
Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study.
Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel.
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases.
[Plasmapheresis in central nervous system disorders].
Amiloride HCl
It is better to be in a clinical trial than not: lessons learnt from clinical neurology--the management of acute multiple sclerosis relapses.

Pages